

**DESCRIPTION**

**Source** Chinese Hamster Ovary cell line, CHO-derived  
Lys18-Ser272, with a C-terminal 6-His tag  
Accession # P24770

**N-terminal Sequence Analysis** Lys18

**Structure / Form** Noncovalently-linked homodimer

**Predicted Molecular Mass** 30 kDa (monomer)

**SPECIFICATIONS**

**SDS-PAGE** 37-43 kDa, reducing conditions

**Activity** Measured by its ability to inhibit rIFN- $\gamma$  mediated protection of HeLa human cervical epithelial carcinoma cells to viral lysis. Meager, A. (1987) in *Lymphokines and Interferons, a Practical Approach*. Clemens, M.J. *et al.* (eds): IRL Press. 129.  
Th ED<sub>50</sub> for this effect is 0.5-3 ng/mL.

**Endotoxin Level** <0.10 EU per 1  $\mu$ g of the protein by the LAL method.

**Purity** >95%, by SDS-PAGE with silver staining.

**Formulation** Lyophilized from a 0.2  $\mu$ m filtered solution in PBS. See Certificate of Analysis for details.

**PREPARATION AND STORAGE**


**Reconstitution** Reconstitute at 500  $\mu$ g/mL in sterile PBS.

**Shipping** The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

**Stability & Storage** Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

**DATA**



**BACKGROUND**

B8R is a secreted Interferon gamma (IFN- $\gamma$ ) binding protein encoded by the open reading frame of the *Vaccinia* virus (smallpox) (1, 2). B8R is a 43 kDa protein and shares only 19% amino acid sequence identity with the extracellular region of the human IFN-gamma Receptor 1 (IFN- $\gamma$  R1). However, B8R binds IFN- $\gamma$  orthologs from multiple species including human, rat, rabbit, bovine, and chicken with high affinity, but it binds mouse IFN- $\gamma$  with low affinity (1, 3, 4). During infection, virally-induced B8R binds and sequesters endogenous IFN- $\gamma$ , thereby suppressing the host immune response and promoting viral immune evasion (5). While B8R is not required for viral replication, it contributes significantly to *Vaccinia* virus virulence and is frequently inactivated prior to *Vaccinia* use in vaccines (5-9). Peptide IFN- $\gamma$  mimetics that activate IFN- $\gamma$  R1 and are not bound and sequestered by B8R have been developed for research and therapeutic use (10, 11).

**References:**

1. Alcami, A. and G.L. Smith (1995) *J. Virol.* **69**:4633.
2. Goebel, S.J. *et al.* (1990) *Virology* **179**:247.
3. Puehler, F. *et al.* (1998) *Virology* **248**:231.
4. Mossman, K. *et al.* (1995) *Virology* **208**:762.
5. Smith, G.L. *et al.* (2013) *J. Gen. Virol.* **94**:2367.
6. Symons, J.A. *et al.* (2002) *J. Gen. Virol.* **83**:1953.
7. Verardi, P.H. *et al.* (2001) *J. Virol.* **75**:11.
8. Denes, B. *et al.* (2006) *J. Gene Med.* **8**:814.
9. Dimier, J. *et al.* (2011) *J. Virol.* **85**:5016.
10. Ahmed, C.M. *et al.* (2007) *J. Immunol.* **178**:4576.
11. Ahmed, C.M. *et al.* (2005) *J. Virol.* **79**:5632.